CU2 Stock Chart & Stats
€2.32
€0.00(0.00%)
At close: 4:00 PM EDT
€2.32
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.19 - €2.96
Previous CloseN/A
Volume0.00
Average Volume (3M)264.00
Market Cap
€419.16M
Enterprise Value€606.88M
Total Cash (Recent Filing)€56.26M
Total Debt (Recent Filing)€76.80M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 02, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding201,524,900
10 Day Avg. Volume99
30 Day Avg. Volume264
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.02Price Target Upside73.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€227.08M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelCerus generates recurring revenue from single-use INTERCEPT kits and reagents required for ongoing blood-component processing. This consumables model can deepen customer retention, align sales with treated blood volumes, and support durable revenue visibility as adoption expands.
Sustained Revenue GrowthDouble-digit product growth across the first half and higher full-year guidance indicate continued commercial expansion rather than a purely temporary improvement. Sustained demand growth can increase operating leverage, broaden the installed customer base, and reinforce Cerus’s market position.
Pipeline And Regulatory ProgressThe INT200 submission and advancing INTERCEPT RBC program create additional product opportunities beyond the current portfolio. Successful regulatory and clinical progress could expand addressable blood-safety applications, strengthen the platform, and provide longer-term growth catalysts.
Bears Say
Continued GAAP LossesCerus has improved its loss profile but remains GAAP unprofitable, so revenue growth has not yet translated into durable bottom-line earnings. Continued losses can restrict internally funded investment, increase reliance on financing, and leave execution sensitive to operating setbacks.
Elevated LeverageDebt running above equity leaves Cerus with a less conservative balance sheet and increases financial risk while profitability remains unproven. Leverage can constrain capital allocation, raise sensitivity to interest costs, and reduce flexibility if growth or cash generation falls short.
Weak Cash ConversionRecent cash generation remains weak despite positive operating cash flow in 2024 and 2025. Slightly negative TTM free cash flow means Cerus is not yet consistently converting improving earnings measures into funding, which may require continued borrowing or tighter investment management.
Cerus News
CU2 FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was €1.19 and its highest was €2.96 in the past 12 months.
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is €419.16M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Nov 02, 2026 which is in 8 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Jul 30, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.012 by €0.003.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 201,524,900 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.012. Following the earnings report the stock price went down -13.6%.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in DE:CU2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.02 (73.15% Upside)
€4.02 (73.15% Upside)
Blogger Sentiment
Bullish
DE:CU2 Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.30%
12-Months-Change
Fundamentals
Return on Equity
-10.31%
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cerus Corp
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CU2 Company Deck
CU2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: double-digit product revenue growth, raised product and IFC guidance, consecutive quarters of positive adjusted EBITDA, meaningful debt refinancing benefits, regulatory progress (PMA submission and upcoming Phase 3 readout), and a clean quality audit. Counterbalancing items include a drop in gross margin (51.4% vs 55.2% prior year) driven by currency and inflationary pressures, reduced government contract revenue this quarter, modest operating cash use for inventory, and regulatory/penetration challenges in Asia-Pacific and for broader IFC adoption. On balance the positives (top-line growth, improving profitability measures, stronger balance sheet flexibility, and regulatory/clinical progress) outweigh the near-term headwinds.View all DE:CU2 earnings summariesCU2 Stock 12 Month Forecast
Average Price Target
€4.02
▲(73.15% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―